Mirvaso, the first treatment targeting the facial erythema of rosacea approved by the European Commission
The European Commission has granted marketing authorisation in Europe for Mirvaso ( Brimonidine ) 3 mg/g gel.
Mirvaso is a long-acting alpha-2 adrenergic receptor that acts rapidly and can last for ...
read article